58,248 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Acquired by Elmind Capital LP

Posted by Brenda Bartman on Jun 18th, 2026

Elmind Capital LP purchased a new position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 58,248 shares of the company’s stock, valued at approximately $2,022,000. Immunocore accounts for about 0.6% of Elmind Capital LP’s investment portfolio, making the stock its 27th biggest position. Elmind Capital LP owned approximately 0.12% of Immunocore at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Primecap Management Co. CA raised its holdings in Immunocore by 5.5% during the 4th quarter. Primecap Management Co. CA now owns 3,961,880 shares of the company’s stock valued at $137,517,000 after acquiring an additional 207,320 shares during the period. Bellevue Group AG raised its holdings in Immunocore by 14.5% during the 3rd quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after acquiring an additional 354,973 shares during the period. Millennium Management LLC raised its holdings in Immunocore by 334.3% during the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after acquiring an additional 974,463 shares during the period. Armistice Capital LLC raised its holdings in Immunocore by 33.3% during the 4th quarter. Armistice Capital LLC now owns 1,098,000 shares of the company’s stock valued at $38,112,000 after acquiring an additional 274,000 shares during the period. Finally, Fiera Capital Corp raised its holdings in Immunocore by 31.4% during the 4th quarter. Fiera Capital Corp now owns 1,044,831 shares of the company’s stock valued at $36,266,000 after acquiring an additional 249,674 shares during the period. Institutional investors own 84.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IMCR shares. Mizuho set a $38.00 target price on shares of Immunocore in a report on Thursday, February 19th. Wall Street Zen raised shares of Immunocore from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Jefferies Financial Group cut shares of Immunocore from a “buy” rating to a “hold” rating and lowered their target price for the company from $48.00 to $33.00 in a report on Monday, March 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Tuesday, April 21st. Finally, Zacks Research raised shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and a consensus price target of $56.71.

Get Our Latest Stock Analysis on IMCR

Immunocore Stock Up 1.3%

IMCR opened at $28.55 on Thursday. The company has a fifty day moving average price of $29.45 and a 200-day moving average price of $32.04. The firm has a market capitalization of $1.45 billion, a P/E ratio of -51.91 and a beta of 0.74. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. Immunocore Holdings PLC Sponsored ADR has a one year low of $27.56 and a one year high of $40.71.

Immunocore (NASDAQ:IMCR – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The firm had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. Equities research analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current fiscal year.

Immunocore Company Profile

(Free Report)

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.